Axcelead DDP and Lilly Sign Research Collaboration Agreement

Axcelead Drug Discovery Partners, Inc. (Axcelead DDP), headquartered in Fujisawa, Kanagawa, Japan, announced a significant partnership with Eli Lilly and Company (Lilly) on September 5. This collaboration focuses on multiple drug discovery programs.

Axcelead DDP is renowned for its proficiency in generating drug candidates, utilizing advanced drug discovery capabilities and innovative technologies, including artificial intelligence. The company leverages its researchers' extensive knowledge and substantial experience to drive progress in drug discovery.

Kengo Okada, Ph.D., Representative Director and CEO of Axcelead DDP, expressed his satisfaction with the collaboration, emphasizing Lilly's recognition of Axcelead DDP's abilities in generating new drug candidates and employing novel drug discovery technologies. He stated, “I am extraordinarily pleased to have entered into a strategic collaboration agreement with Lilly, a leading global pharmaceutical company. I firmly believe Lilly selected us as a drug discovery partner in recognition of our capabilities to generate new drug candidates and our wide-range novel drug discovery technologies.” Okada underscored Axcelead DDP's commitment to enhancing Lilly’s pipeline through its innovative platform, aiming to deliver high-quality new drug candidates that could potentially become life-changing medicines for people worldwide.

The agreement entails that Axcelead DDP will receive an upfront payment and additional milestone payments contingent on the progress of each drug discovery program.

Axcelead DDP, established in July 2017, is Japan’s first drug discovery solution provider, having inherited the drug discovery platform from Takeda Pharmaceutical. The company integrates screening, medicinal chemistry, pharmacology/biology, DMPK, and safety research functions into a single, state-of-the-art research center equipped with an original compound library. The integration of advanced AI capabilities into Axcelead DDP’s services allows for the rapid creation of high-quality drug candidates. By harnessing these strengths, Axcelead DDP addresses various challenges in drug discovery.

For further details, please visit Axcelead DDP’s official website.